Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations

a case-control study

John R. McLaughlin, Harvey A. Risch, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry T. Lynch, Beth Karlan, David Fishman, Barry Rosen, Susan L. Neuhausen, Kenneth Offit, Noah Kauff, Susan Domchek, Nadine Tung, Eitan Friedman, William Foulkes, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

Background: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. Methods: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95% CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. Findings: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0·56 [95% CI 0·45-0·71]; p

Original languageEnglish
Pages (from-to)26-34
Number of pages9
JournalThe Lancet Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Ovarian Neoplasms
Case-Control Studies
Mutation
Oral Contraceptives
Tubal Sterilization
Parity
Breast Feeding
Canada
Odds Ratio
BRCA2 Gene
BRCA1 Gene
Reproductive History
Ontario
Menstrual Cycle
Ovulation
Genes
Registries
Parturition
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations : a case-control study. / McLaughlin, John R.; Risch, Harvey A.; Lubinski, Jan; Moller, Pal; Ghadirian, Parviz; Lynch, Henry T.; Karlan, Beth; Fishman, David; Rosen, Barry; Neuhausen, Susan L.; Offit, Kenneth; Kauff, Noah; Domchek, Susan; Tung, Nadine; Friedman, Eitan; Foulkes, William; Sun, Ping; Narod, Steven A.

In: The Lancet Oncology, Vol. 8, No. 1, 01.2007, p. 26-34.

Research output: Contribution to journalArticle

McLaughlin, JR, Risch, HA, Lubinski, J, Moller, P, Ghadirian, P, Lynch, HT, Karlan, B, Fishman, D, Rosen, B, Neuhausen, SL, Offit, K, Kauff, N, Domchek, S, Tung, N, Friedman, E, Foulkes, W, Sun, P & Narod, SA 2007, 'Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study', The Lancet Oncology, vol. 8, no. 1, pp. 26-34. https://doi.org/10.1016/S1470-2045(06)70983-4
McLaughlin, John R. ; Risch, Harvey A. ; Lubinski, Jan ; Moller, Pal ; Ghadirian, Parviz ; Lynch, Henry T. ; Karlan, Beth ; Fishman, David ; Rosen, Barry ; Neuhausen, Susan L. ; Offit, Kenneth ; Kauff, Noah ; Domchek, Susan ; Tung, Nadine ; Friedman, Eitan ; Foulkes, William ; Sun, Ping ; Narod, Steven A. / Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations : a case-control study. In: The Lancet Oncology. 2007 ; Vol. 8, No. 1. pp. 26-34.
@article{bb7f63af37b04123a3ce5a7726e7e708,
title = "Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study",
abstract = "Background: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. Methods: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95{\%} CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. Findings: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0·56 [95{\%} CI 0·45-0·71]; p",
author = "McLaughlin, {John R.} and Risch, {Harvey A.} and Jan Lubinski and Pal Moller and Parviz Ghadirian and Lynch, {Henry T.} and Beth Karlan and David Fishman and Barry Rosen and Neuhausen, {Susan L.} and Kenneth Offit and Noah Kauff and Susan Domchek and Nadine Tung and Eitan Friedman and William Foulkes and Ping Sun and Narod, {Steven A.}",
year = "2007",
month = "1",
doi = "10.1016/S1470-2045(06)70983-4",
language = "English",
volume = "8",
pages = "26--34",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations

T2 - a case-control study

AU - McLaughlin, John R.

AU - Risch, Harvey A.

AU - Lubinski, Jan

AU - Moller, Pal

AU - Ghadirian, Parviz

AU - Lynch, Henry T.

AU - Karlan, Beth

AU - Fishman, David

AU - Rosen, Barry

AU - Neuhausen, Susan L.

AU - Offit, Kenneth

AU - Kauff, Noah

AU - Domchek, Susan

AU - Tung, Nadine

AU - Friedman, Eitan

AU - Foulkes, William

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2007/1

Y1 - 2007/1

N2 - Background: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. Methods: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95% CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. Findings: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0·56 [95% CI 0·45-0·71]; p

AB - Background: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. Methods: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95% CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. Findings: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0·56 [95% CI 0·45-0·71]; p

UR - http://www.scopus.com/inward/record.url?scp=33845680235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845680235&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(06)70983-4

DO - 10.1016/S1470-2045(06)70983-4

M3 - Article

VL - 8

SP - 26

EP - 34

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -